Brief: Gyre Therapeutics Inc Receives Ind Approval From China's Nmpa To Evaluate F230 For Treatment Of Pulmonary Arterial Hypertension
30/05/2024 22:24
Gyre Therapeutics Inc GYRE.O :
* GYRE THERAPEUTICS INC: RECEIVES IND APPROVAL FROM CHINA'S
NMPA
TO EVALUATE F230 FOR TREATMENT OF PULMONARY ARTERIAL
HYPERTENSION
Source text for Eikon: ID:nGNX4M7pFL
Further company coverage: GYRE.O
Recent news on Gyre Therapeutics
See all newsBrief: Gyre Therapeutics - Enters Employment Agreement With Ying Luo As CEO - SEC Filing
Gyre Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Gyre Therapeutics, Inc. expected to post a loss of 13 cents a share - Earnings Preview
Brief: Gyre Therapeutics Reports Second Quarter 2026
Gyre Therapeutics Q2 revenue beats estimates on higher ETUARY sales volumes